本研究旨在分析中性粒细胞与淋巴细胞比值(NLR)是否与宫颈癌患者的放射线肠道炎症(RE)有关联。我们选择的是从2020年10月至2021年7月期间接受了放射疗法的39名宫颈癌病人作为我们的研究群体,并根据其NLR的最优切割点将其划分为低NLR组和...本研究旨在分析中性粒细胞与淋巴细胞比值(NLR)是否与宫颈癌患者的放射线肠道炎症(RE)有关联。我们选择的是从2020年10月至2021年7月期间接受了放射疗法的39名宫颈癌病人作为我们的研究群体,并根据其NLR的最优切割点将其划分为低NLR组和高NLR组。分别根据RTOG标准和GSRS量表对患者RE严重程度进行评估,将RTOG分级为1级定义为轻度RE,2级定义为中度RE,3级和4级的定义为严重RE。分析放疗前NLR水平与宫颈癌患者放疗过程中RE严重程度之间的联系。经过对ROC曲线的分析后,我们确定了放射治疗前的NLR的最优切割点数值是2.76。基于RTOG与GSRS评分系统的结果显示,高NLR的患者比那些较低NLR的患者更易发生严重的RE,并且他们的GSRS评分也明显更高(P The aim of this study is to explore the connection between the neutrophil to lymphocyte ratio (NLR) and radiation enteritis (RE) in patients undergoing radiation therapy for cervical cancer. 39 patients with cervical cancer who received radiotherapy between October 2020 and July 2021 were analyzed in this study. They were categorized into low and high NLR groups based on the optimal NLR cut-off value in the ROC curve. The assessment of patients’ RE severity was determined using the RTOG criteria (Radiation Therapy Oncology Group) criteria and GSRS (Gastrointestinal Symptoms Rating Scales) respectively, and grade 1 of RTOG was defined as mild RE, grade 2 as moderate RE, grade 3 and 4 as severe RE. In this study, we examined how the level of NLR prior to radiotherapy is linked to the intensity of radiation esophagitis in cervical cancer patients. The ROC curve analysis revealed that the ideal threshold for NLR before radiotherapy was determined to be 2.76. The RTOG criteria and GSRS scale revealed that the high NLR group had a greater proportion of patients with severe RE than their low NLR counterparts, as well as an increased GSRS score (all P < 0.05). Clinical stage, N stage, and NLR level were found to have significant associations with the development of moderate-severe RE in logistic univariate regression analysis. However, in logistic multivariate regression analysis, it was revealed that the independent risk factors for moderate-severe RE occurrence were NLR level and N stage. NLR was determined to have diagnostic value for predicting moderate-severe RE in cervical cancer patients undergoing radiotherapy (P < 0.05). NLR is associated with the severity of RE during radiotherapy for cervical cancer patients, and it shows a certain predictive value for the occurrence of moderate-severe RE.展开更多
目的系统评价不同驱动基因突变状态下非小细胞肺癌(NSCLC)相关静脉血栓栓塞症(VTE)发生率,并进一步探讨基因突变状态与VTE发病风险的关系。方法计算机检索PubMed、EMbase、Web of Science、Cochrane Library、中国知网、万方和维普数据...目的系统评价不同驱动基因突变状态下非小细胞肺癌(NSCLC)相关静脉血栓栓塞症(VTE)发生率,并进一步探讨基因突变状态与VTE发病风险的关系。方法计算机检索PubMed、EMbase、Web of Science、Cochrane Library、中国知网、万方和维普数据库,搜索NSCLC相关驱动基因突变状态与VTE发生率关系的相关研究,检索时限为建库至2023年7月3日,采用Stata 14.0软件进行分析。结果共纳入文献32篇,总样本量为18032例。Meta分析结果显示,在携带驱动基因突变的肺癌患者中VTE总发生率为19%[95%CI(15%~23%)];ROS1基因融合状态下VTE并发症发生率最高,为31%[95%CI(22%~39%)];ALK/ROS1基因融合/重排以及PD-L1表达阳性的存在与VTE发生风险增加有关[ALK:OR=2.28,95%CI(1.89~2.76);ROS1:OR=3.18,95%CI(1.89~5.35);PD-L1:OR=1.85,95%CI(1.25~2.72)],而EGFR/KRAS基因突变与VTE发生风险无相关性[EGFR:OR=1.16,95%CI(0.75~1.80);KRAS:OR=1.54,95%CI(0.98~2.43)]。结论不同驱动基因突变状态下NSCLC相关VTE并发症的发生率存在明显差异,ALK/ROS1基因融合/重排以及PD-L1表达阳性的存在与VTE发生风险增加有关,而EGFR/KRAS基因突变与VTE发生风险无明显相关性。展开更多
原发灶不明肿瘤(carcinoma of unknown primary,CUP)是一种广泛存在的且具有多种临床表现的恶性转移性疾病。目前在世界范围内,CUP是最常见的恶性肿瘤之一,在诊断的癌症中占2.3%~5.0%。其中,表现为未知原发癌的转移淋巴结在头颈部CUP患...原发灶不明肿瘤(carcinoma of unknown primary,CUP)是一种广泛存在的且具有多种临床表现的恶性转移性疾病。目前在世界范围内,CUP是最常见的恶性肿瘤之一,在诊断的癌症中占2.3%~5.0%。其中,表现为未知原发癌的转移淋巴结在头颈部CUP患者中占24%~36%[1-4]。研究发现,原发部位不明的头颈部鳞状细胞癌约占头颈部鳞癌的2%~5%[5]。本研究分析2例原发灶误诊的颈部淋巴结癌,并综合历年来对原发灶不明颈部肿瘤及口咽恶性肿瘤的文献介绍,为原发灶不明颈部肿瘤的发现诊断提供新思路和新见解。展开更多
文摘本研究旨在分析中性粒细胞与淋巴细胞比值(NLR)是否与宫颈癌患者的放射线肠道炎症(RE)有关联。我们选择的是从2020年10月至2021年7月期间接受了放射疗法的39名宫颈癌病人作为我们的研究群体,并根据其NLR的最优切割点将其划分为低NLR组和高NLR组。分别根据RTOG标准和GSRS量表对患者RE严重程度进行评估,将RTOG分级为1级定义为轻度RE,2级定义为中度RE,3级和4级的定义为严重RE。分析放疗前NLR水平与宫颈癌患者放疗过程中RE严重程度之间的联系。经过对ROC曲线的分析后,我们确定了放射治疗前的NLR的最优切割点数值是2.76。基于RTOG与GSRS评分系统的结果显示,高NLR的患者比那些较低NLR的患者更易发生严重的RE,并且他们的GSRS评分也明显更高(P The aim of this study is to explore the connection between the neutrophil to lymphocyte ratio (NLR) and radiation enteritis (RE) in patients undergoing radiation therapy for cervical cancer. 39 patients with cervical cancer who received radiotherapy between October 2020 and July 2021 were analyzed in this study. They were categorized into low and high NLR groups based on the optimal NLR cut-off value in the ROC curve. The assessment of patients’ RE severity was determined using the RTOG criteria (Radiation Therapy Oncology Group) criteria and GSRS (Gastrointestinal Symptoms Rating Scales) respectively, and grade 1 of RTOG was defined as mild RE, grade 2 as moderate RE, grade 3 and 4 as severe RE. In this study, we examined how the level of NLR prior to radiotherapy is linked to the intensity of radiation esophagitis in cervical cancer patients. The ROC curve analysis revealed that the ideal threshold for NLR before radiotherapy was determined to be 2.76. The RTOG criteria and GSRS scale revealed that the high NLR group had a greater proportion of patients with severe RE than their low NLR counterparts, as well as an increased GSRS score (all P < 0.05). Clinical stage, N stage, and NLR level were found to have significant associations with the development of moderate-severe RE in logistic univariate regression analysis. However, in logistic multivariate regression analysis, it was revealed that the independent risk factors for moderate-severe RE occurrence were NLR level and N stage. NLR was determined to have diagnostic value for predicting moderate-severe RE in cervical cancer patients undergoing radiotherapy (P < 0.05). NLR is associated with the severity of RE during radiotherapy for cervical cancer patients, and it shows a certain predictive value for the occurrence of moderate-severe RE.
文摘目的系统评价不同驱动基因突变状态下非小细胞肺癌(NSCLC)相关静脉血栓栓塞症(VTE)发生率,并进一步探讨基因突变状态与VTE发病风险的关系。方法计算机检索PubMed、EMbase、Web of Science、Cochrane Library、中国知网、万方和维普数据库,搜索NSCLC相关驱动基因突变状态与VTE发生率关系的相关研究,检索时限为建库至2023年7月3日,采用Stata 14.0软件进行分析。结果共纳入文献32篇,总样本量为18032例。Meta分析结果显示,在携带驱动基因突变的肺癌患者中VTE总发生率为19%[95%CI(15%~23%)];ROS1基因融合状态下VTE并发症发生率最高,为31%[95%CI(22%~39%)];ALK/ROS1基因融合/重排以及PD-L1表达阳性的存在与VTE发生风险增加有关[ALK:OR=2.28,95%CI(1.89~2.76);ROS1:OR=3.18,95%CI(1.89~5.35);PD-L1:OR=1.85,95%CI(1.25~2.72)],而EGFR/KRAS基因突变与VTE发生风险无相关性[EGFR:OR=1.16,95%CI(0.75~1.80);KRAS:OR=1.54,95%CI(0.98~2.43)]。结论不同驱动基因突变状态下NSCLC相关VTE并发症的发生率存在明显差异,ALK/ROS1基因融合/重排以及PD-L1表达阳性的存在与VTE发生风险增加有关,而EGFR/KRAS基因突变与VTE发生风险无明显相关性。
文摘原发灶不明肿瘤(carcinoma of unknown primary,CUP)是一种广泛存在的且具有多种临床表现的恶性转移性疾病。目前在世界范围内,CUP是最常见的恶性肿瘤之一,在诊断的癌症中占2.3%~5.0%。其中,表现为未知原发癌的转移淋巴结在头颈部CUP患者中占24%~36%[1-4]。研究发现,原发部位不明的头颈部鳞状细胞癌约占头颈部鳞癌的2%~5%[5]。本研究分析2例原发灶误诊的颈部淋巴结癌,并综合历年来对原发灶不明颈部肿瘤及口咽恶性肿瘤的文献介绍,为原发灶不明颈部肿瘤的发现诊断提供新思路和新见解。
